Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Perfadex® Plus has received patent approval in Europe

XVIVO Perfusion has received European patent approval for the company’s ready to use product Perfadex® Plus for cold preservation of lungs. Perfadex® Plus was launched in Europe and the US in 2018.As XVIVO Perfusion has previously reported, the company has developed a new ready to use version of its product for cold preservation of lungs. Patent applications for the new formulation, which is called Perfadex® Plus, have been submitted in all important markets and the European patent authority has now approved the patent in Europe. Perfadex® Plus was launched in the principal markets, the US

ORGANOCLICK AB (PUBL) PUBLISHES ITS INTERIM REPORT FOR Q2 2019

"We reached two big milestones during the second quarter. In May, our customer Fredahl Rydéns launched the burial coffin Saga based on our biocomposite OrganoComp®. The second milestone is that OrganoClick for the first time, as a listed company, reached a positive EBIT for a full quarter."  Translation from CEO Mårten Hellbergs comments to the Interim Report.   Q2, 1 April – 30 June 2019 The Group compared with 2018 » The net revenue amounted to SEK 32.71 (30.64) million » EBITDA of SEK 3.73 (0.96) million » Result before tax of SEK -0.27 (-1.08) million 1 January –

Flex LNG – AGM Notice

Flex LNG Limited (the “Company”) announces that its 2019 Annual General Meeting will be held on September 13, 2019. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements for 2018 can be found in the links below and on our website at www.flexlng.com.    August 21, 2019 The Board of Directors Flex LNG Limited Hamilton, Bermuda      This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act or the Continuing Obligations of Oslo Børs.

Storytel enters into a new agreement with Bonnierförlagen

Storytel Sweden AB (“Storytel”) has today entered into a three-year term agreement with Bonnierförlagen. This means that Storytel’s approximately 400,000 Swedish customers once again will have access to the full catalogue of Bonnierförlagen, including new releases, from 1 September 2019.Storytel has since 1 April 2019 not been able to offer new releases from Bonnierförlagen due to a disagreement between the parties as to content of a new cooperation agreement. Today, a new three-year term agreement has been entered into, meaning that Storytel’s Swedish customers again will be able to

ZICCUM AB Half Year Report Q2 2019

Summary of Half Year Report second quarter 2019: This has been an eventful year for Ziccum.Summary of Half Year Report, second quarter 2019 2019 has been eventful for Ziccum: We have filed a patent application for an important component in the development of new vaccines, Adenovirus. This has resulted in several industrial players showing new interest in our technology. We also announced that we have entered into a Contract Research agreement with one of these companies, aimed at evaluating LaminarPace ™ in combination with their own project. In the second quarter we also got together

Presentation of the Q2 report

Oslo, Norway (21 August 2019) A presentation will be held via webcast at 10 am CET, Wednesday 21stAugust 2019, followed by a Q&A session. Please follow the below link to join the webcast; https://webtv.hegnar.no/presentation.php?webcastId=98042744 For more information, please contact: Kjetil Ramsøy CEO, NattoPharma E-mail: kjetil.ramsoy@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Aker Solutions to Deliver Umbilicals for the Dalma Gas Development Project in the United Arab Emirates (UAE)

August 21, 2019 - Aker Solutions has won an order from ADNOC (Abu Dhabi National Oil Company) to deliver subsea umbilicals for the Dalma gas development project located offshore UAE in the shallow waters of the Persian Gulf. "This is the first subsea umbilical award by ADNOC in the UAE and the first subsea award for Aker Solutions in the Persian Gulf," said Luis Araujo, chief executive officer of Aker Solutions. "We are very pleased with the opportunity to further develop our relationship with ADNOC and to demonstrate our umbilical capabilities in the region." The value of the

Cxense ASA announces second quarter and first half 2019 results

Oslo, Norway - 21 August 2019 - Cxense ASA today reported financial results for the second quarter and first half ending 30 June 2019. Highlights: - Received offer from Piano (event after reporting period) ·Voluntary cash offer at NOK 16 per share ·Unanimously recommended by BoD and management ·Pre-accepted by 53% of outstanding shares, including shares of BoD and management - Continue executing on strategic plan ·Customer touchpoints and product development capacity to increase as new sales, customer success, engineering and data science resources are

Update on the Phase III NEPTUNE trial

21 August 2019 07:00 BST Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer AstraZeneca today announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care (SoC) platinum-based chemotherapy in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) patients. The trial was performed in an all-comers population, and the primary analysis

Hansa Biopharma to participate in three upcoming investor conferences

Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs’ Biotech Symposium in London, Morgan Stanley’s Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in LondonLund, Sweden August 21, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences: · The Goldman Sachs Ninth Annual Biotech

OssDsign AB (publ) publishes Q2 2019 interim report

OssDsign CEO Anders Lundqvist: “Overall this has been an historic quarter for OssDsign – one in which we became a public company and in which we have taken further control of the key markets for our future growth. Our present financial position and ongoing organizational developments will allow us to capitalize on the multiple substantial opportunities for growth.”The second quarter in figures: · Net sales amounted to TSEK 3 454 (2 908). · Loss after taxes amounted to TSEK 18 330 (14 324). · Loss per share was SEK 1.3 (3.0). · Cash flow from current operations was TSEK -13 917

New forecast: Global turbulence to hit Swedish growth

Growth in the Swedish economy is now so slow that we can refer to it as a full-on deterioration, reports Handelsbanken in its new Global Macro Forecast. “We foresee a cooling-off, and expect the Riksbank to keep the repo rate negative for several years to come”, says the bank’s Chief Economist, Christina Nyman.During the summer, the trade war between the US and China has escalated, while the risk of a hard Brexit is increasing. Nothing points to a quick solution, and the major global uncertainty is set to persist, according to Handelsbanken’s forecast. “Naturally, central banks, led by

GROSS PROFIT GROWTH OF 14 PERCENT, GROWTH ON ALL MARKETS

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs. SECOND QUARTER, APRIL – JUNE 2019 · Net sales increased by 9.1% to MSEK 70.8 (64.9) · Gross profit increased 13.8% to MSEK 55.5 (48.8) · EBIT was MSEK -0.4 (-1.2) · Earnings after tax was MSEK -0.4 (-1.7) · Earnings per share was, basic SEK -0.05 (-0.24), diluted SEK -0.05 (-0.23) FIRST HALF YEAR, JANUARY – JUNE 2019  · Net sales increased by 12.0% to MSEK 137.1 (122.5) · Gross profit increased by 16.3% to MSEK 106.4 (91.5) · EBIT

NattoPharma continues growth in the second quarter

Oslo, Norway (21 August 2019) NattoPharma increased revenues by 10% in the second quarter and 22% for the first half of the year. Adjusted EBITA in the quarter came in at NOK 0,9 million, yet another profitable quarter for the company. CEO, Kjetil Ramsøy: “We continue to deliver growth with first half year revenues of NOK 58 million, representing an increase of more than 22% on the same period in 2018, and another quarter with a positive EBITDA line. At the same time, we have made pleasing progress with our new ingredient with positive results from the studies that have been

Alimak Group: Interim report January – June 2019

Solid Group performance, mixed outcomes within the business areas · Order intake decrease mainly stemming from weak development in Construction Equipment. Another all-time high of orders in a quarter for After Sales · Strong revenue growth in Construction Equipment compensates slight decrease in Industrial Equipment · Margin improvement both year-over-year and sequentially for the Group, EPS increase of 37% Second quarter · Order intake decreased by 3% to MSEK 1,150 (1,182) with an organic decrease of 7% · Revenue grew by 7% to MSEK 1,193 (1,112) with an organic

Recalculation of warrants in Insplorion AB (publ) due to completed rights issue

Due to the rights issue, which was successfully completed before the summer, recalculation has been made in accordance with the terms of the two outstanding warrants programs regarding the subscription price and/or the number of shares that each warrant entitles to subscription for.Insplorion AB (publ) has two outstanding warrant programs, TO2018/2020 which is aimed at staff and key people in the company and TO1 2018/2023 which was distributed to all shareholders in connection with the financing agreement with ESGO, signed at the beginning of 2018 and traded on Spotlight Stock Market (INSP

Gradientech announces Notice of Allowance from United States Patent and Trademark Office

Uppsala, August 21, 2019. Gradientech AB, today announces that the company has received a Notice of Allowance from the United States Patent and Trademark Office for the patent application no. 14/903,032, "Use of a Fluidic Device".The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacterial sample within a microfluidic controlled environment that is part of the technology platform of the company's diagnostic system QuickMIC™ for ultra-rapid antibiotic susceptibility testing (AST). A Notice of Allowance signifies that Gradientech will be

Change in number of shares in BrainCool AB (publ)

Conversion of convertible notes into shares, as part of the financing agreement announced January 22, 2019.The number of convertible notes converted on August 20, 2019, was 10. The number of convertible notes remaining under the fourth tranche is 12. The number of shares and the number of votes before the conversion was 39 936 771. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have increased by 175 131. The total number of shares and total number of votes after this conversion and once

Skanska to expand Harbor line at Hisingen, Gothenburg, Sweden, for about SEK 1.3 billion

Skanska has signed an agreement with Trafikverket, the Swedish Transport Administration, to build double lanes for the freight railway Hamnbanan, the Eriksberg-Pölsebo stage, in Gothenburg, Sweden. The contract is worth about SEK 1.3 billion, which will be included in the order bookings for Skanska Sweden for the third quarter of 2019.The extension is 1,900 meters, of which 1,100 meters will be a tunnel, north of the existing single track. The project also includes construction of temporary tracks for traffic diversion, demolition of an existing facility including a bridge, new pedestrian

Rikshem’s interim report January–June 2019

Rikshem presented its interim report for January–June 2019 today. Profit after tax amounted to MSEK 1,126 (1,144). Rental income increased 4.9 percent to MSEK 1,442 (1,374). Rental income for existing properties rose 3.3 percent (4.5).“The revenue trend for the first half of the year was favorable. This was not fully reflected in our net operating income as a result of high damage costs, which impacted property expenses. We are continuing our work to strengthen the property management organization and improve the quality of our property management, which will yield results in the long term.

Second quarter report 2019

Continued strong growth and improved results21 August 2019 · Net sales increased by 10 percent to MSEK 2,472 (2,252) in the second quarter 2019. Net sales increased by 8 percent in Sweden, 20 percent in Denmark, 7 percent in Norway, 13 percent in Finland and remained unchanged in Ireland. · Adjusted operating income[2] increased by 24 percent to MSEK 115 (92), corresponding to a margin of 4.6 (4.1) percent. Adjusted operating income increased in all segments. · Income for the period improved to MSEK 50 (32). Earnings per share rose to SEK 0.78 (0.49). The increase compared to

Interim report Q2 2019

SECOND QUARTER 2019 · Total revenues amounted to EUR 5.7 million (EUR 6.0 million) representing a decrease of 6.1%. · Organic growth amounted to -8.8% (24.5%). · Adjusted EBITDA decreased by 10.7% to EUR 2.9 million (EUR 3.2 million), corresponding to a margin of 51.1% (53.7%). · Adjusted operating profit amounted to EUR 2.0 million (EUR 2.9 million), corresponding to a margin of 35.1% (48.3%). · Profit for the period increased by EUR 1.5 million from EUR 0.2 million to EUR 1.7 million. · Earnings per share before dilution amounted to EUR 0.04 (EUR 0.01) representing an

Webstep Q2 2019: Strong market, but limited growth capacity

Oslo 21 August 2019: Webstep ASA reports a slight revenue decrease in the first half of 2019, due to lower capacity year-on-year. The EBITDA margin remains solid, although affected by one-off costs and use of subcontractors. The order book remains strong. Additional measures to re-establish growth capacity have been implemented to enable Webstep to capitalise on the continued attractive market momentum.Webstep ASA (“the Group” or “Webstep”) recorded consolidated revenues in the second quarter of NOK 162.0 million, down 7.4 per cent from the same quarter last year. The decline is mainly

Statement from the independent bid committee in KappAhl in relation to the public tender offer by Mellby Gård

This statement is made by the independent bid committee of the board of directors of KappAhl AB (publ) (the "Committee") ("KappAhl" or the "Company") pursuant to Section II.19 of Nasdaq Stockholm's Takeover Rules (the "Takeover Rules"). Conclusion The Committee unanimously recommends the shareholders of KappAhl to accept Mellby Gårds public tender offer.Background On 29 July 2019 a public tender offer was made by Mellby Gård AB ("Mellby Gård") to the shareholders of KappAhl to tender all their shares in KappAhl to Mellby Gård (the "Offer"). Mellby Gård is offering a cash

There are no items matching the current filter
There are no more items matching the current filter
Back to top